• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Molecular Interactions of Thrombin.

作者信息

Tulinsky A

机构信息

Dept. of Chemistry, Michigan State University, East Lansing 48824-1322, USA.

出版信息

Semin Thromb Hemost. 1996;22(2):117-24. doi: 10.1055/s-2007-998998.

DOI:10.1055/s-2007-998998
PMID:8807707
Abstract

Thrombin possesses at least three independent binding sites for substrate, inhibitor, and co-factor molecules, four counting the Na+ ion binding site. The S1 subsite of the active site is specific for an arginine side group, while S2 is a more extended apolar site. The highly electropositive S' subsites of the fibrinogen exosite circumnavigate about a third of the thrombin surface, although evidence suggests molecular recognition of a tetra- or pentapeptide sequence is sufficient for binding. Another highly electropositive region of thrombin that binds the second kringle of prothrombin is the heparin binding site. All three of these sites display distinct binding modes with different molecules. These can arise from tolerance of imprecision of binding and/or from reversal of ligand main chain direction in active site and fibrinogen exosite binding. Preliminary indications suggest similar principles may apply to the heparin site. Such varied behavior easily accounts for the diversity of thrombin functions at the molecular level. The complexity of the behavior is compounded even more by a Na+ ion binding site that produces a procoagulant fast form of thrombin. The slow form (in the absence of Na+ ion) is anticoagulant.

摘要

相似文献

1
Molecular Interactions of Thrombin.
Semin Thromb Hemost. 1996;22(2):117-24. doi: 10.1055/s-2007-998998.
2
Active site and exosite binding of alpha-thrombin.α-凝血酶的活性位点和别构位点结合
Blood Coagul Fibrinolysis. 1993 Apr;4(2):305-12. doi: 10.1097/00001721-199304000-00012.
3
The Na+ binding channel of human coagulation proteases: novel insights on the structure and allosteric modulation revealed by molecular surface analysis.人凝血蛋白酶的钠离子结合通道:通过分子表面分析揭示的结构和变构调节新见解。
Biophys Chem. 2006 Feb 1;119(3):282-94. doi: 10.1016/j.bpc.2005.10.001. Epub 2005 Nov 9.
4
Energetics of thrombin-thrombomodulin interaction.凝血酶-血栓调节蛋白相互作用的能量学
Biochemistry. 1997 Jun 3;36(22):6674-81. doi: 10.1021/bi962766a.
5
Thrombin specificity.凝血酶特异性
Thromb Haemost. 1995 Jul;74(1):129-33.
6
Oligonucleotide inhibitors of human thrombin that bind distinct epitopes.结合不同表位的人凝血酶的寡核苷酸抑制剂。
J Mol Biol. 1997 Oct 10;272(5):688-98. doi: 10.1006/jmbi.1997.1275.
7
Nonpolar interactions of thrombin S' subsites with its bivalent inhibitor: methyl scan of the inhibitor linker.凝血酶S'亚位点与其二价抑制剂的非极性相互作用:抑制剂连接子的甲基扫描
Biochemistry. 1997 Nov 4;36(44):13494-502. doi: 10.1021/bi970857h.
8
Molecular dynamics simulations of thrombin inhibitors at the S' subsites of thrombin.
Drug Des Discov. 1994 Jul;12(1):1-17.
9
The crystal structure of alpha-thrombin-hirunorm IV complex reveals a novel specificity site recognition mode.α-凝血酶-希鲁诺姆IV复合物的晶体结构揭示了一种新的特异性位点识别模式。
Protein Sci. 1999 Jan;8(1):91-5. doi: 10.1110/ps.8.1.91.
10
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.基于三肽的α-酮杂环作为凝血酶抑制剂的深入研究。S1'亚位点的有效利用及其对基于结构的药物设计的意义。
J Med Chem. 2005 Mar 24;48(6):1984-2008. doi: 10.1021/jm0303857.

引用本文的文献

1
Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling.超越抗凝:非维生素 K 口服抗凝剂(NOACs)在炎症和蛋白酶激活受体信号转导中的综合评价。
Int J Mol Sci. 2024 Aug 10;25(16):8727. doi: 10.3390/ijms25168727.
2
Thrombin: An Approach to Developing a Higher-Order Reference Material and Reference Measurement Procedure for Substance Identity, Amount, and Biological Activities.凝血酶:开发用于物质鉴定、含量和生物活性的高阶参考物质及参考测量程序的方法。
J Res Natl Inst Stand Technol. 2020 Jul 29;125:125021. doi: 10.6028/jres.125.021. eCollection 2020.
3
In Vitro Antithrombotic, Hematological Toxicity, and Inhibitor Studies of Protocatechuic, Isovanillic, and -Hydroxybenzoic Acids from (Carr.) Bur.
原儿茶酸、香草酸和 - 羟基苯甲酸体外抗血栓形成、血液毒性和抑制剂研究
Molecules. 2022 May 29;27(11):3496. doi: 10.3390/molecules27113496.
4
Exosite Binding in Thrombin: A Global Structural/Dynamic Overview of Complexes with Aptamers and Other Ligands.凝血酶的外切位点结合:适体和其他配体复合物的整体结构/动力学概述。
Int J Mol Sci. 2021 Oct 6;22(19):10803. doi: 10.3390/ijms221910803.
5
Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin.重新审视抗血栓治疗药物;sculptin,一种新型的、特异的、竞争性的、可逆的、可切割的、紧密结合的凝血酶抑制剂。
Sci Rep. 2017 May 3;7(1):1431. doi: 10.1038/s41598-017-01486-w.
6
Viscoelasticity and Ultrastructure in Coagulation and Inflammation: Two Diverse Techniques, One Conclusion.凝血与炎症中的粘弹性和超微结构:两种不同技术,一个结论。
Inflammation. 2015 Aug;38(4):1707-26. doi: 10.1007/s10753-015-0148-7.
7
Direct thrombin inhibitors' potential efficacy in Alzheimer's disease.直接凝血酶抑制剂在阿尔茨海默病中的潜在疗效。
Am J Alzheimers Dis Other Demen. 2012 Dec;27(8):564-7. doi: 10.1177/1533317512465667.
8
Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.儿科人群中的肝素诱导的血小板减少症:当前文献综述
J Pediatr Pharmacol Ther. 2012 Jan;17(1):12-30. doi: 10.5863/1551-6776-17.1.12.
9
Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.达比加群:新型口服抗凝药物出血并发症的药理学和管理综述。
J Med Toxicol. 2011 Dec;7(4):281-7. doi: 10.1007/s13181-011-0178-y.
10
Direct thrombin inhibitors.直接凝血酶抑制剂。
Br J Clin Pharmacol. 2011 Oct;72(4):581-92. doi: 10.1111/j.1365-2125.2011.03916.x.